Compare Illinois Tool Works Inc. (ITW) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Merck & Co., Inc. — how do they compare? Illinois Tool Works Inc. trades at $271.88 (market cap $78.17B), while Merck & Co., Inc. trades at $125.97 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 3.9× Illinois Tool Works Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| ITW | MRK | |
|---|---|---|
Market Cap | $78.17B | $307.25B |
Sector | Industrials | Health |
52-Week High | $299.60 | $129.52 |
52-Week Low | $241.07 | $77.60 |
Enterprise Value | $86.49B | $350.66B |
Dividend Yield | 2.37% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $271.99, down 1.47% on the day, with a bullish technical signal from moving averages and a consensus price target of $288.25. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected soon. Strong profitability is evident with a 19.32% net margin and 96.88% ROE, though valuation multiples like P/E of 25.23 are elevated. Recent news highlights product launches and dividend declarations, supporting a stable outlook.
The outlook for ITW is cautiously optimistic, with earnings momentum and dividend stability offering support, but high valuation and mixed analyst ratings pose risks. Investors should weigh solid fundamentals against potential headwinds from economic cycles and competitive pressures.
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
